PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of splusSpringerOpen.comSubmit OnlineRegisterThis journalThis article
 
Springerplus. 2016; 5(1): 733.
Published online 2016 June 16. doi:  10.1186/s40064-016-2498-5
PMCID: PMC4909690

Biosynthesis of Se-methyl-seleno-l-cysteine in Basidiomycetes fungus Lentinula edodes (Berk.) Pegler

Abstract

Background

The aim of the current study was to investigate whether the Basidiomycetes fungus Lentinula edodes can biosynthesize Se-methyl-seleno-l-cysteine, a seleno-amino acid with strong anticancer activity, and to optimize the culture conditions for its biosynthesis. We hypothesize that preparations obtained from Se-methyl-seleno-l-cysteine-enriched mycelia from this medicinal mushroom would possess stronger cancer-preventive properties than current preparations.

Results

By optimizing the concentration of selenium in the culture medium, we increased the mycelial concentration of Se-methyl-seleno-l-cysteine from essentially non-detectable levels to 120 µg/g dry weight. Significantly elevated levels of this amino acid also correlated with significant (twofold) inhibition of mycelial growth. Increases in the concentration of mycelial Se-methyl-seleno-l-cysteine appeared to be highly correlated with the enhanced biosynthesis of selenomethionine and total selenium content in mycelium.

Conclusions

We have demonstrated that in L. edodes, enhanced biosynthesis of this non-protein amino acid eliminates excess selenium.

Keywords: Lentinula edodes, Selenium, Se-methyl-seleno-l-cysteine, Selenomethionine

Background

Nearly four decades ago, a significant inverse correlation between human cancer mortality and dietary selenium intake was reported by Schrauzer and White (Schrauzer and White 1978); the level of selenium in whole blood is directly proportional to dietary selenium intake. Selenium is, therefore, a trace element that appears to function as a key nutrient in cancer chemoprevention (Vinceti et al. 2014). This important health effect is connected to stimulation of the immune system, protection of cells against the effects of free radicals by selenium-dependent antioxidant enzymes, and inhibition of tumor cell growth by selenium metabolites (El-Bayoumy 2001; Rayman 2005; Brozmanova et al. 2010). Despite its benefits, selenium has a narrow margin of safety that limits the doses used in chemoprevention (Reid et al. 2004).

The bioavailability, tissue distribution, and toxicity of selenium strongly depend on the form ingested. Organic forms of selenium have higher bioavailability and lower toxicity than inorganic species (Brozmanova et al. 2010). For a long time, l-selenomethionine (SeMet) (Fig. 1) was considered to be the organic selenium compound with the most potent anticancer activity (Schrauzer 2000). That opinion seemed to be confirmed by experiments conducted by Clark et al. (Clark et al. 1996), who determined that supplementation with selenium yeast at a dose corresponding to 200 μg of selenium per day appear to decrease overall human cancer mortality by 50 % versus controls. Selenium yeast is a recognized source of organic food-form selenium produced by fermenting Saccharomyces cerevisiae (baker’s or brewer’s yeast) in a selenium-enriched media. Since approximately 85 % of selenium in selenium yeast occurs in the form of selenomethionine (Ip et al. 2000), the anticancer effect seemed to be due to selenomethionine (Redman et al. 1998). To confirm these initial findings, the largest-ever prostate cancer prevention trial, the Selenium and Vitamin E Cancer Prevention Trial (SELECT), was designed and carried out. Selenium was administered orally in the form of selenomethionine at a dose of 200 μg for a planned follow-up of a minimum of 7 years and a maximum of 12 years. Initially, SELECT uncovered no reduction in the risk of prostate cancer following ingestion of selenium or vitamin E supplements but did detect a statistically nonsignificant increase in prostate cancer risk with vitamin E ingestion (Lippman et al. 2009). Updated data from SELECT confirmed these preliminary results (Klein et al. 2011; Kristal et al. 2014).

Fig. 1
The structures of: a l-selenomethionine and b Se-methyl-seleno-l-cysteine

The substantial differences between the results of Clark et al. (Clark et al. 1996) and the results of the SELECT project indicate that selenomethionine was most likely not the molecule primarily responsible for the extremely favorable protective activity of selenium yeast against cancer (Sharma and Amin 2013). The more recent anticancer research focused on Se-methyl-seleno-l-cysteine (MeSeCys) (Fig. 1). Numerous studies have demonstrated the efficacy of this non-protein selenoamino acid in preventing and treating cancer (Bhattacharya 2011; Rayman 2005; Rayman 2012). Se-methyl-seleno-l-cysteine in garlic and broccoli has been shown to more efficiently reduce the incidence of mammary and colon cancer in rats than selenomethionine in yeast or broccoli supplemented with selenite (Finley et al. 2001). This effect may be due to substantial differences in the mechanisms of chemoprevention by Se-methyl-seleno-l-cysteine and other selenocompounds (Suzuki et al. 2010).

Lentinulaedodes (Berk.) Pegler, the shiitake mushroom, is both medicinal and edible. The antitumor activity of lentinan and other pharmacologically active polysaccharides and polysaccharide-protein complexes in the shiitake extracts results mainly from activation of the host immune system (Zhang et al. 2005). The mechanism by which selenium exerts anticancer and immunomodulatory activities differs from the action of L. edodes polysaccharide fractions, but similar pharmacological effects suggest that these agents may act synergistically. Therefore, we hypothesized that high concentrations of the organic forms of selenium in L. edodes biomass would increase the immune system-enhancing and anticancer activities of L. edodes extracts.

We previously demonstrated that submerged cultivation of L. edodes effectively caused selenium from the cultivation medium to accumulate in mycelia in the form of organic compounds such as selenomethionine, selenocysteine and Se-containing polysaccharides (Turło et al. 2007, 2010). The current study sought to determine whether L. edodes mycelia grown in medium supplemented with selenium accumulate this element in the form of Se-methyl-seleno-l-cysteine and to identify the optimum concentration of selenium in the culture medium for Se-methyl-seleno-l-cysteine biosynthesis.

Methods

Microorganisms and cultivation media

The Lentinula edodes (Berk.) Pegler strain used in this study was American Type Culture Collection (ATCC, Manassas, USA) strain 48085. The seed culture was grown under the conditions described previously (Suzuki et al. 2010; Zhang et al. 2005).

Optimization of culture medium for Se-methyl-seleno-l-cysteine biosynthesis

We used the culture medium optimized in our previous research for biosynthesis of SeMet, containing 5 % glucose, 1 % yeast extract, 1.5 % soybean extract, and 0.1 % (w/v) KH2PO4 (Turło et al. 2010). The medium was either not fortified or enriched with selenium to a concentration of 5, 10, 15, 20, or 30 μg/mL via the addition of sodium selenite. Fermentation medium was inoculated with the seed culture at 10 % (v/v) and cultivated at 26 °C on a rotary shaker at 110 rev/min for 14 days. Mycelia were harvested via filtration, freeze dried, and used to determine the concentration of Se-methyl-seleno-l-cysteine.

Extraction of Se-methyl-seleno-l-cysteine

Against decomposition of Se-methyl-seleno-l-cysteine, extraction was performed at 4 °C (Arnault and Auger 2006). Twenty milliliters of 50 mM HCl were added to 0.5 g of homogenized mycelia and sonicated for 20 min. The mixture was then stirred for 6 h at 4 °C and stored at 4 °C. The samples were filtered under reduced pressure, the filtrate was freeze-dried, and the resulting dry extract was stored at 4 °C in the dark. Dried extract was redissolved in water to the appropriate concentration for determination of MeSeCys.

Analytical determination of Se-methyl-seleno-l-cysteine

Determination of Se-methyl-seleno-l-cysteine was performed with high-performance liquid chromatography (HPLC) of o-phthaldialdehyde derivative, compared with the retention time of a Se-methyl-seleno-l-cysteine standard (Sigma, Saint Louis, USA). Our method was a modification of reported previously (Turło et al. 2007).

Samples were prepared by dissolving 0.1 g of mycelium extract in 10 ml of HPLC-grade water. The assay was performed using a calibration curve (external standard). Se-methyl-seleno-l-cysteine recovery under the conditions of extraction and analysis was determined by subjecting the standard to the same procedure as the samples. HPLC was carried out using a Shimadzu Manufacturing INC (Canby, USA) gradient system (SCL-10AVP controller, two LC-10ATVP pumps, CTO-10ACVP oven) with a fluorescence detector (LaChrom L-7480, Merck-Hitachi, Darmstadt, Germany). C18 column 250 × 4 mm; Phenomenex (Torrance, USA), Luna 2 with appropriate guard column was used. Eluent A consisted of 50 mM sodium acetate buffer (pH 7.0) containing 0.1 % acetonitrile while eluent B was methanol. The gradient breakpoints (min/%B) were (0/40), (6/45), (12/45), (20/63), (38/63), and (49/100). The temperature was 32 °C, the injection volume was 20 μL, and the flow rate was 1.2 mL/min. The excitation wavelength was 340 nm, and the emission wavelength was 435 nm. Se-methyl-seleno-l-cysteine retention occurred at 14.9 min.

Analytical determination of selenomethionine

Selenomethionine content was determined by reverse-phase HPLC of o-phthaldialdehyde derivative (OPA method) as previously described (Turło et al. 2007). The conditions of the analysis were as follows:

Eluent A was 100 mM sodium acetate buffer pH 7.2 containing 0.1 % of acetonitrile, eluent B was methanol.

The gradient breakpoints were as follows (min/%B): (0/45), (6/45), (12/50), (20/63), (38/63), (49/100), (55/100). Temperature was 32 °C, injection volume 20 μL and flow rate 1.2 mL/min. The chosen excitation wavelength was 340 nm and emission wavelength 435 nm. The selenomethionine retention time was 40.2 min.

Analytical determination of total selenium

Reverse-phase HPLC of mineralized samples was used to determine the total selenium content, as previously described (Turło et al. 2009). Namely, a 0.1 % solution of diaminonaphthalene (DAN) in 0.1 M HCl was prepared and stored in the dark at 4 °C. The pH of each of digested sample dissolved in 8 mL of Suprapur water was adjusted to 1.8–2 by adding HCl or 7 M NH3·H2O, as needed. One milliliter of DAN was added to each sample and the mixtures were heated for 45 min at 75 °C. After cooling, 3 mL of cyclohexane was added and the samples were shaken vigorously for 1 min to extract the fluorescent piazselenol. Prior to RP HPLC determination the samples were stored in the dark. The sample solutions were diluted with cyclohexane as needed. A blank digest was manipulated similarly for use as a control. Selenium standard solutions (6.25–1000 ng Se/mL) were prepared under the same conditions. The fluorescence was a linear function of the concentration of Se in the tested range (correlation coefficient, R = 0.999).

The RP-HPLC conditions were as follows: eluent, acetonitrile: flow rate, 1.4 mL/min; temperature, 25 °C; injection volume, 20 μL. For fluorimetric analysis, the excitation wavelength was 378 nm and emission wavelength was 557 nm. The piazselenol retention time was 3.1 min.

Statistical analysis

Data were analyzed using one-way analysis of variance or t Student test with the statistical package STATISTICA 10 (StatSoft). Arcsine transformation was used to equal variances before one-way analysis of variance. Post-hoc analysis was performed with the least-significant difference test. Cell viability data were analyzed using t Student test. Differences were considered to be significant when p value <0.05.

Results

Extraction and determination of Se-methyl-seleno-l-cysteine

Cold extraction (with 50 mM HCl at 4 °C) was chosen in order to avoid decomposition of Se-methyl-seleno-l-cysteine in the resulting extract. Se-methyl-seleno-l-cysteine is stable at room temperature, but extraction at high temperature cause its substantial loss. In general, organic selenium species remain stable for up to 1 year in aqueous solution at pH 4.5 when stored at 4–20 °C in the dark (Amoako et al. 2007). Extraction overnight at 4 °C in 50 mM HCl (2:1 v/w) was previously used for routine quantification of Se-methyl-seleno-l-cysteine in plant samples (Ellis et al. 2004). The current applications are the first use of this cold method for the isolation of this non-protein amino acid from fungal biomass. When developing the extraction method, we have tested the recovery of MeSeCys under different conditions. Under low-temperature (4 °C) extraction conditions the recovery of MeSeCys was 98.8 % (±2.3 %), while at a temperature of 100 °C (Soxhlet extraction)—only 4 % (±1.2 %), n = 5.

Determination of amino acids with high-performance liquid chromatography (HPLC) of o-phthaldialdehyde derivatives is described as a method of good selectivity and efficiency (Hammel et al. 1997; Bartolomeo and Maisano 2006). The standard HPLC equipment and relatively cheap C18 columns used are significant advantages of this approach. The detection limit for most of the OPA amino acid derivatives is in range 25–50 fmol (Hammel et al. 1997). In our previous research, we successfully applied this method for determination of selenomethionine in mycelial hydrolysates (Turło et al. 2007). Currently, this approach was successfully used for determination of Se-methyl-seleno-l-cysteine. The detection limit (LOD) for the OPA Se-methyl-seleno-l-cysteine derivative was 63 fmol, limit of quantification (LOQ)—211 fmol. The fluorescence was a linear function of the concentration of MeSeCys in the tested range of 0–25 nmol/mL (correlation coefficient R = 0.999, equation for standard curve was y = 2.182E−06x, where y-MeSeCys concentration, x—peak area). The reproducibility of the method was assessed by calculating the relative standard deviations for MeSeCys standard solutions (n = 5); the values ranged from 1.35 to 4.1 %. The standard deviation of the blank was used to estimate the detection and quantification limits of the complete procedure. The lowest determined MeSeCys concentration in the mycelial extract was 79 pM, thus it was nearly 400-fold higher than limit of quantification (LOQ). The Fig. 2 shows the representative chromatograms of the extract from not Se-enriched mycelium, the extract from mycelium cultivated in medium enriched with 20 μg/mL Se and the mixture of extract from not Se-enriched mycelium with MeSeCys standard solution.

Fig. 2
Representative chromatograms of: a extract from not Se-enriched mycelium, b mixture of extract from not Se-enriched mycelium with MeSeCys standard solution, c extract from mycelium cultivated in medium enriched with 20 μg/mL Se

Effect of medium supplementation on mycelial growth

The medium that we selected on the ground of the previous research was associated with a satisfactory yield of mushroom mycelium (10 g of dry weight/1 L of the medium after 10 days of cultivation) (Table 1). According to our previous results increasing the selenium concentration (in the form of sodium selenite) had a dose-dependent inhibitory effect on mycelial growth (Turło et al. 2007, 2010). When the concentration selenium in the medium was greater than 15 μg/mL, the mycelial growth decreased.

Table 1
Relationship between the selenium concentration in the culture medium and the total selenium, selenomethionine and Se-methylselenocysteine contents in L. edodes mycelia

Biosynthesis of Se-methyl-seleno-l-cysteine in L. edodes

We wanted to evaluate whether the presence of sodium selenite in medium stimulated biosynthesis of MeSeCys by mycelium of L. edodes and, if so, to find the optimal concentration. The concentration of Se-methyl-seleno-l-cysteine rose from not detectable content in mycelium cultivated in non-enriched medium to 120 μg/g dry mass of mycelium grown in medium enriched with 20 μg/mL of Se. When the concentration of Se in the medium was greater than 20 μg/mL, Se-methyl-seleno-l-cysteine content in the mycelium decreased (Table 1).

Biosynthesis of selenomethionine in L. edodes

The amount of selenomethionine in the harvested mycelial biomass increased with the increasing concentration of selenium. The optimum concentration was 20 μg/mL, which provided a concentration of 672 μg/g dry mass in the harvested mycelium. Higher concentrations of selenium inhibited selenomethionine biosynthesis (Table 1).

Discussion

Despite the sizeable interest, the metabolism of selenium by higher fungi remains poorly understood. This process is most widely characterized in plants, motivating us to compare our data on the biosynthesis of Se-methyl-seleno-l-cysteine in L. edodes with reports concerning plants. According to Ellis and Salt (Ellis and Salt 2003), plants primarily take up selenium as selenate or selenite, which are then metabolized via the sulfur assimilation pathway to yield selenomethionine, selenocysteine, and other selenium analogs of various sulfur metabolites. Non-specific incorporation of selenoamino acids into proteins is thought to contribute to selenium toxicity (Ellis et al. 2004). A proposed mechanism of selenium tolerance in plants is the specific conversion of potentially toxic selenoamino acids into non-protein derivatives such as Se-methyl-seleno-l-cysteine (Wang et al. 1999). Our previous studies indicated that L. edodes can incorporate selenium into the proteins, mainly in the form of selenomethionine (Turło et al. 2007). Toxicity occurred when selenomethionine was present at >300 µg/g of fungal biomass and a total selenium content of 1100 µg/g, resulting in substantial inhibition of mycelial growth (Turło et al. 2010). We also found that excess selenium is eliminated via its reduction to elemental selenium (Turło et al. 2010), what was 2 years later confirmed by Tsivileva et al. (2012).

In the current study by optimizing the concentration of selenium in the culture medium, we increased the mycelial concentration of Se-methyl-seleno-l-cysteine from essentially non-detectable levels to 120 μg/g D.W. (Table 1). However, only 4–11 % of the selenium accumulated in the form of Se-methyl-seleno-l-cysteine (Fig. 3).

Fig. 3
Percentage of selenium accumulated in the form of Se-methyl-seleno-l-cysteine against the total content of selenium in the mycelium

Increases in the concentration of mycelial Se-methyl-seleno-l-cysteine appeared to be highly correlated with the enhanced biosynthesis of selenomethionine. MetSeCys content in cultivated mycelia also rose as total selenium content increased (Table 1). As it was stated above, the MeSeCys contents in mycelium well correlate with the total selenium and SeMet. The presented graph (Fig. 4) indicates for selenium content up to 1000 μg/g and the MetSeCys up to 300 μg/g the correlation is linear (r = 0.992, p < 0.005, r = 0.997, p < 0.001) while for the higher concentrations nonlinear.

Fig. 4
Correlation of Se-methyl-seleno-l-cysteine content in mycelium with a selenomethionine. content and b total selenium content in cultivated mycelia

It suggests that elimination of excess selenium via SeMet and MetSeCys biosynthesis is not the sole way of detoxification in the case of high selenium concentration. As mentioned above, in high selenium concentrations, the excess selenium is also eliminated via its reduction to elemental red selenium (Turło et al. 2010; Tsivileva et al. 2012). It can be assumed that, as in plants, incorporation of selenomethionine into the structures of mushroom proteins likely contributes to selenium toxicity: mycelial growth was significantly reduced (p < 0.0005) when the concentration of selenomethionine in the mycelia was >300 µg/g of dry mass. This effect was accompanied by a nearly twofold increase in the concentration of Se-methyl-seleno-l-cysteine (Table 1). These observations are consistent with the assumption that the biosynthesis of non-protein derivatives of selenium is a method of detoxification.

Conclusions

Here we have demonstrated that in the Basidiomycetes fungus L. edodes, enhanced biosynthesis of the non-protein amino acid Se-methyl-seleno-l-cysteine eliminates excess selenium. Significantly elevated levels of this amino acid correlated with significant (twofold) inhibition of mycelial growth. By optimizing the concentration of selenium in the culture medium, we increased the mycelial concentration of Se-methyl-seleno-l-cysteine from essentially non-detectable levels to 120 µg/g dry weight. The further problem is to examine whether, according to our hypothesis, high concentration of MeSeCys in extracts of the fungus increases the anti-cancer effect.

Authors’ contributions

MK: participated in study design, carried out the biotechnological part of the study. SG: participated in biotechnological part of the study and drafted the manuscript. PP: carried out the analytical part of the study. MD: participated in analytical part of the study and performed statistical analysis. JT: conceived of the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We want to thank master’s student Małgorzata Ciołek for her great commitment and help in conducting experimental works.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by Grant FW26/N/15/16 from the Medical University of Warsaw, Poland.

Abbreviations

MeSeCys
Se-methyl-seleno-l-cysteine, Se-methyl selenocysteine (CID:105024)
SeMet
l-selenomethionine or 2-amino-4-methylselanyl-butanoic acid (CID:147004)
RP-HPLC
reverse-phase high-performance liquid chromatography
LOD
limit of detection
LOQ
limit of quantification
D.W.
dry weight
Uql
under quantification limit

Contributor Information

M. Klimaszewska, lp.ude.muw@akswezsamilk.annezram.

S. Górska, lp.ude.muw@aksrog.ardnas.

M. Dawidowski, lp.ude.muw@ikswodiwadm.

P. Podsadni, lp.ude.muw@indasdopp.

J. Turło, Phone: +48 22 5720647, lp.ude.muw@olrut.agiwdaj.

References

  • Amoako O, Kahakachchi CL, Dodova EN, Uden PC, Tyson JF. Speciation, quantification and stability of selenomethionine, Se-(methylseleno)cysteine and selenomethionine Se-oxide in yeast-based nutritional supplements. J Anal At Spectrom. 2007;22:938–946. doi: 10.1039/b703381h. [Cross Ref]
  • Arnault I, Auger J. Seleno-compounds in garlic and onion. J Chromatog A. 2006;1112(1–2):23–30. doi: 10.1016/j.chroma.2006.01.036. [PubMed] [Cross Ref]
  • Bartolomeo MP, Maisano F. Validation of a reverse-phase HPLC method for quantitative amino acid analysis. J Biomolecular Techniques. 2006;17(2):131–137. [PMC free article] [PubMed]
  • Bhattacharya A. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opin Drug Deliv. 2011;8(6):749–763. doi: 10.1517/17425247.2011.571672. [PMC free article] [PubMed] [Cross Ref]
  • Brozmanova J, Manikova D, Vlckova V, Chovanec M. Selenium: a double-edged sword for defense and offence in cancer. Arch Toxicol. 2010;84(12):919–938. doi: 10.1007/s00204-010-0595-8. [PubMed] [Cross Ref]
  • Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J. Effects of selenium supplementation for prevention in patients with carcinoma of the skin. JAMA. 1996;6(276):1957–1985. doi: 10.1001/jama.1996.03540240035027. [PubMed] [Cross Ref]
  • El-Bayoumy K. The protective role of selenium on genetic damage and on cancer. Mutat Res. 2001;475(1–2):123–139. doi: 10.1016/S0027-5107(01)00075-6. [PubMed] [Cross Ref]
  • Ellis DR, Salt DE. Plants, selenium and human health. Curr Opin Plant Biol. 2003;6(3):273–279. doi: 10.1016/S1369-5266(03)00030-X. [PubMed] [Cross Ref]
  • Ellis DR, Sors TG, Brunk DG, Albrecht C, Orser C, Lahner B, Wood KV, Harris HH, Pickering IJ, Salt DE. Production of Se-methylselenocysteine in transgenic plants expressing selenocysteine methyltransferase. BMC Plant Biol. 2004;4:1–11. doi: 10.1186/1471-2229-4-1. [PMC free article] [PubMed] [Cross Ref]
  • Finley JW, Ip C, Lisk DJ, Davis CD, Hiuntze KJ, Whanger PD. Cancer-protective properties of high-selenium broccoli. J Agric Food Chem. 2001;49(5):2679–2683. doi: 10.1021/jf0014821. [PubMed] [Cross Ref]
  • Hammel C, Kyriakopoulos A, Rosick U, Behne D. Identication of selenocysteine and selenomethionine in protein hydrolysates by high-performance liquid chromatography of their o-phthaldialdehyde derivatives. Analyst. 1997;122(11):1359–1363. doi: 10.1039/a704054g. [PubMed] [Cross Ref]
  • Ip C, Birringer M, Block E, Koterbai M, Tyson JF, Uden PC, Lisk DJ. Chemical speciation influences comparative activity of selenium-enriched garlic and yeast in mammary cancer prevention. J Agric Food Chem. 2000;48(6):2062–2070. doi: 10.1021/jf000051f. [PubMed] [Cross Ref]
  • Klein EA, Thompson IM, Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E, Cancer Prevention Trial (Select) JAMA. 2011;306(14):1549–1556. doi: 10.1001/jama.2011.1437. [PMC free article] [PubMed] [Cross Ref]
  • Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Jr, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014;106(3):djt456. doi: 10.1093/jnci/djt456. [PMC free article] [PubMed] [Cross Ref]
  • Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Jr, Baker LH, Coltman CA., Jr Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E, Cancer Prevention Trial (Select) JAMA. 2009;301(1):39–51. doi: 10.1001/jama.2008.864. [PMC free article] [PubMed] [Cross Ref]
  • Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc. 2005;64(4):527–542. doi: 10.1079/PNS2005467. [PubMed] [Cross Ref]
  • Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc. 2005;64(4):527–542. doi: 10.1079/PNS2005467. [PubMed] [Cross Ref]
  • Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256–1268. doi: 10.1016/S0140-6736(11)61452-9. [PubMed] [Cross Ref]
  • Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, Roe D, Payne CM, Nelson MA. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. 1998;125(1–2):103–110. doi: 10.1016/S0304-3835(97)00497-7. [PubMed] [Cross Ref]
  • Reid ME, Stratton MS, Lillico AJ, Fakih M, Natarajan R, Clark LC. A report of high dose selenium supplementation: response and toxicities. J Trace Elem Med Biol. 2004;18(1):69–74. doi: 10.1016/j.jtemb.2004.03.004. [PubMed] [Cross Ref]
  • Schrauzer GN. Selenomethionine: a review of its nutritional significance, metabolism, and toxicity. J Nutr. 2000;130(7):1653–1656. [PubMed]
  • Schrauzer GN, White DA. Selenium in human nutrition: dietary intakes and effects of supplementation. Bioinorg Chem. 1978;8(4):303–318. doi: 10.1016/S0006-3061(00)80164-7. [PubMed] [Cross Ref]
  • Sharma AK, Amin S. Post select: selenium on trial. Future Med Chem. 2013;5(2):163–174. doi: 10.4155/fmc.12.203. [PubMed] [Cross Ref]
  • Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H. Differential apoptotic response of human cancer cells to organoselenium compounds. Cancer Chemother Pharmacol. 2010;66(3):475–484. doi: 10.1007/s00280-009-1183-6. [PubMed] [Cross Ref]
  • Tsivileva OM, Loshchinina EA, Pankratov AN, Burashnikova MM, Yurasov NA, Bylinkina NN, Kazarinov IA, Nikitina VE. Biodegradation of an organoselenium compound to elemental selenium by Lentinula edodes (Shiitake) Mushroom. Biol Trace Elem Res. 2012;149(1):97–101. doi: 10.1007/s12011-012-9399-4. [PubMed] [Cross Ref]
  • Turło J, Gutkowska B, Malinowska E. Relationship between selenium, selenomethionine and selenocysteine content in submerged cultivated mycelium of Lentinus edodes (Berk.) Acta Chromatogr. 2007;18:36–48.
  • Turło J, Gutkowska B, Herold F, Łuczak I. Investigation of the kinetics of selenium accumulation by Lentinula edodes (Berk.). mycelial culture by use of reversed-phase high-performance liquid chromatography with fluorimetric detection. Acta Chromatogr. 2009;21(1):1–11. doi: 10.1556/AChrom.21.2009.1.1. [Cross Ref]
  • Turło J, Gutkowska B, Herold F. Effect of selenium enrichment on antioxidant activities and chemical composition of Lentinula edodes (Berk.) Pegler. Mycelial extracts. Food Chem Toxicol. 2010;48(4):1085–1091. doi: 10.1016/j.fct.2010.01.030. [PubMed] [Cross Ref]
  • Turło J, Gutkowska B, Herold F, Klimaszewska M, Suchocki P. Optimization of selenium-enriched mycelium of Lentinula edodes (Berk.) Pegler—as a food supplement. Food Biotechnol. 2010;24:180–196. doi: 10.1080/08905436.2010.482446. [Cross Ref]
  • Vinceti M, Dennert G, Crespi CM, Zwahlen M, Brinkman M, Zeegers MP, Horneber M, D’Amico R, Del Giovane C. Selenium for preventing cancer. Cochrane Database Syst Rev. 2014;30(3):CD005195. [PMC free article] [PubMed]
  • Wang Y, Bock A, Neuhierl B. Acquisition of selenium tolerance by a selenium non-accumulating Astragalus species via selection. BioFactors. 1999;9(1):3–10. doi: 10.1002/biof.5520090102. [PubMed] [Cross Ref]
  • Zhang L, Li X, Xu X, Zeng F. Correlation between antitumor activity, molecular weight, and conformation of lentinan. Carbohydr Res. 2005;340(8):1515–1521. doi: 10.1016/j.carres.2005.02.032. [PubMed] [Cross Ref]

Articles from SpringerPlus are provided here courtesy of Springer-Verlag